Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases International Review of Neurobiology Series

Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer?s and Parkinson?s, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases; Harnessing Neurogenesis in the Adult Brain ? A Role in Type 2 Diabetes Mellitus and Alzheimer?s disease; and much more.

1. Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative diseases
Kenneth Maiese
2. Antidiabetic drugs for Alzheimer´s and Parkinson´s diseases: Repurposing insulin, metformin and thiazolidinediones
Susana Cardoso and Paula I. Moreira
3. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Christian Hölscher
4. Repurposing GLP1 agonists for neurodegenerative diseases
Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina and Per Svenningsson
5. A role for Sodium Glucose coTransporter 2 inhibitors (SGLT2i) in the treatment of Alzheimer's disease?
Russell Esterline, Jan Oscarsson and Jeffrey Burns
6. Ketotherapeutics for neurodegenerative diseases
Nicholas G. Norwitz, Javier Gilbert Jaramillo, Kieran Clarke and Adrian Soto
7. Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases
Yahyah Aman, Brent Ryan, Silje Bøen Torsetnes, Anne-Brita Knapskog, Leiv Otto Watne, William A. McEwan and Evandro Fei Fang
8. Cellular senescence in aging and age-related disorders: Implications for neurodegenerative diseases
Erin O. Wissler Gerdes, Yi Zhu, Bettina M. Weigand, Utkarsh Tripathi, Terence C. Burns, Tamar Tchkonia and James L. Kirkland
9. Harnessing neurogenesis in the adult brain—A role in type-2-diabetes mellitus and Alzheimer’s disease
Orly Lazarov, Richard D. Minshall and Marcelo G. Bonini
10. Hormesis: A therapeutic strategic approach in the treatment of neurodegenerative disease
Edward J. Calabrese, Mark P. Mattson, Gaurav Dhawan, Rachna Kapoor, Vittorio Calabrese and James Giordano

Grażyna Söderbom, PhD is founder of Klipspringer AB. She received her BSc 1st Class Hons in Pharmacology & Toxicology from King’s College, London and PhD in Neuroscience from the University of London. She spent one year of her undergraduate studies investigating the role of the AT2-receptor subtype at Ciba-Geigy under the tutelage of Dr Marc de Gasparo. As a Wellcome Trust PhD Scholar in Prof. Peter Jenner’s Neurodegenerative Research Group, Grażyna focused on the aetiology of Parkinson’s disease, specifically the relevance of antioxidant enzymes in the basal ganglia and Parkinson’s pathogenesis. After working as a Post-Doctoral Research Fellow at the Clinical Age Research Unit at King’s College Hospital, Grażyna joined Zeneca/AstraZeneca Pharmaceuticals, which included five years as Global Brand Manager in Cardiovascular Medicine in Sweden. She was involved in the global marketing and communications behind the antihypertensive Atacand® and the launch of Atacand Plus®. Having discovered a strong interest in strategic medical communications, Grażyna launched Klipspringer in 2013, which specializes in scientific, medical and strategic writing and consultation for Academia, Bio-Pharma and beyond. Grażyna is passionate about “all things science”, especially neuroscience, and the effective sharing of scientific knowledge to all levels of audiences. She has published scientific research of her own and now supports others in their scientific and medical communications. Grażyna is particularly interested in the potential implications of the link between metabolic disease and neurodegenerative disorders.
Russell Esterline, PhD is currently a VP Global Medicines Leader at AstraZeneca Pharmaceuticals leading the advancement of late stage metabolic products towards registration and approval and beyond. He received his B.S. in Chemistry from Juniata College and his PhD in Toxicology from Rutgers University/UMDNJ Joint Graduate Program in Toxicology. He completed his Post-Doc